Research Article
A Phase IV Study of the Safety and Efficacy of CinnoPar® in Iranian Patients with Osteoporosis
Table 2
Incidence of adverse events by system organ class.
| | System organ class | N (%) | Preferred term name | N (%) |
| | Cardiac disorders | 1 (1) | Tachycardia | 1 (1) | | Endocrine disorders | 7 (4) | Hypercalcemia | 7 (4) | | Gastrointestinal disorders | 7 (4) | Nausea | 6 (3) | | Vomiting | 1 (1) | | Dyspepsia | 2 (1) | | General disorders and administration site conditions | 7 (4) | Pain | 6 (3) | | Asthenia | 1 (1) | | Injection site pain | 1 (1) | | Musculoskeletal and connective tissue disorders | 3 (2) | Muscle spasms | 2 (1) | | Spinal fracture | 1 (1) | | Nervous system disorders | 5 (3) | Headache | 2 (1) | | Insomnia | 2 (1) | | Seizure | 1 (1) | | Dizziness | 2 (1) | | Respiratory, thoracic, and mediastinal disorders | 2 (1) | Dyspnoea | 2 (1) | | Skin and subcutaneous tissue disorders | 2 (1) | Rash | 2 (1) | | Vascular disorders | 1 (1) | Hypotension | 1 (1) | | Patients with at least 1 AE, total | | | 21 (11) |
|
|
